tradingkey.logo

Bionano Genomics Inc

BNGO
View Detailed Chart
1.700USD
-0.020-1.16%
Close 11/04, 16:00ETQuotes delayed by 15 min
6.65MMarket Cap
LossP/E TTM

Bionano Genomics Inc

1.700
-0.020-1.16%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.16%

5 Days

-9.09%

1 Month

-11.46%

6 Months

-58.02%

Year to Date

-90.18%

1 Year

-89.98%

View Detailed Chart

TradingKey Stock Score of Bionano Genomics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bionano Genomics Inc's Score

Industry at a Glance

Industry Ranking
149 / 210
Overall Ranking
388 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
9.500
Target Price
+452.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bionano Genomics Inc Highlights

StrengthsRisks
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.78M.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.42M shares, increasing 45.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.

Bionano Genomics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Bionano Genomics Inc Info

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
Ticker SymbolBNGO
CompanyBionano Genomics Inc
CEODr. R. Erik Holmlin, Ph.D.
Websitehttps://bionano.com/
KeyAI